Immunotherapy with blinatumomab leads to a strongly improved survival rate—from 66% to 93%—for children with an aggressive form of acute lymphoblastic leukemia (ALL). They also had fewer side effects from the treatment. ...
Apr 26, 2023
0
51
Late-breaking research reveals a major treatment advance for adults with newly diagnosed B lineage acute lymphoblastic leukemia (ALL). The randomized phase 3 study E1910 evaluated blinatumomab immunotherapy in patients with ...
Dec 13, 2022
0
3
A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved ...
Dec 7, 2020
0
4
(HealthDay)—Chemotherapy-free induction and consolidation first-line treatment with dasatinib and blinatumomab is associated with a high incidence of molecular response and survival in adults with Philadelphia chromosome ...
Oct 22, 2020
0
1
New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic ...
Dec 10, 2019
0
1
A study led by The University of Texas MD Anderson Cancer Center showed that treatment combining lower doses of chemotherapy with the monoclonal antibody inotuzumab ozogamicin (INO), with or without the drug blinatumomab, ...
Dec 10, 2019
0
2
Patients living with a specific type of leukemia will have access to a new immunotherapy treatment on the NHS in England.
Jun 20, 2019
0
1
Patients living with a specific type of leukaemia will not have access to a new treatment after it failed to win provisional recommendation for use on the NHS in England.
Mar 8, 2019
0
1
A Phase III clinical trial involving 101 centers in 21 countries revealed the monoclonal antibody blinatumomab to be more effective than standard chemotherapy for treatment of advanced acute lymphoblastic leukemia (ALL). ...
Mar 1, 2017
0
137
